Latest! Several new crown vaccines from around the world have entered Phase III clinical trials, and mass vaccinations in Russia have been launched.

Read: WHO: There are 9 new crown vaccines in Phase III clinical trials worldwide, with China accounting for 4.
the world's new crown epidemic continues to develop, India's growing number of confirmed cases hit a new world record, europe's multi-country outbreak rebounded sharply.
6:30 a.m. Beijing time on September 8, there were more than 27.45 million newly confirmed cases and more than 890,000 cumulative deaths worldwide.
vaccine as an important means of prevention and treatment of infectious diseases, people of all countries have long looked forward to, how is the development of vaccines? When will mass vaccinations be 2000? At WHO's regular launch on 4 September, WHO Chief Scientist Sumia Swaminathan said that more than 30 new crown vaccines worldwide were in clinical trials, nine of which were in Phase III clinical trials, and that the situation was very positive, with a large number of candidates.
expect some vaccines to be tested in Phase III clinical trials by the end of this year or early next year, followed by mass production.
At the 2020 China International Trade fair on services in Beijing on September 5-9, two Chinese companies exhibited three new crown pneumonia inactivated vaccines, and many people gathered around the exhibition area and scanned the yards to make appointments for the new crown vaccine, as if to win.
1. According to the joint prevention and control mechanism of the State Council, there are currently 4 new crown virus vaccines in China that have started international Phase III.phase clinical trials, including the New Coronavirus Recombinant New Coronavirus Vaccine developed by the Beijing Institute of Biological Products, Wuhan Biological Products Research Institute and Keying Holding Biotechnology Co., Ltd., respectively, and the adenovirus recombinant vaccine developed by Chen Wei team of the Military Medical Research Institute of the Academy of Military Sciences.
China National Pharmaceutical Group and china CDC Virus Control Institute: Inactivated vaccine Photo Source: News On September 5, two new crown inactivated vaccines from China National Pharmaceutical Group debuted at the 2020 China International Trade Fair in China, produced by Wuhan Institute of Biological Products and Beijing Institute of Biological Products, respectively.
At present, the two new crown inactivated vaccines have entered Phase III. clinical trials, trials are being carried out in the United Arab Emirates, Bahrain, Peru, Morocco, Argentina and other countries and regions, has been in the group of 50,000 people, sample population covering 115 countries, all aspects of progress are world-leading.
production capacity, it is reported that China Bio in Beijing and Wuhan, two biological products research institutes have built a high-grade new crown vaccine production workshop, the two workshops a total annual production capacity of up to 300 million doses.
, on July 22 this year, China has officially launched the emergency use of the new crown vaccine.
pharmaceutical group China Bio-New Crown Inactivated Vaccine has been the first to be approved for emergency use.
china, the vaccines have received clinical trial approvals from more than a dozen countries.
July 26, the clinical phase III trial of the vaccine was launched in Abu Dhabi, United Arab Emirates, and soon 15,000 volunteers signed up.
, a subsidiary of China National Pharmaceutical Group, said the new vaccine could go on sale in December.
Koxing Biological and Experimental Animal Research Institute of the Chinese Academy of Medical Sciences: Inactivated Vaccine Photo Source: News China Science and Technology Cosing Biotechnology Co., D.C. The new crown candidate vaccine is an inactivated vaccine, currently in Brazil, Indonesia and other countries in phase III clinical research, vaccine industrialization construction has also been completed.
September 5th, a new coronavirus inactivated vaccine, "Kelleford", was also on display at the booth of The 2020 China International Trade Fair, Kexing Holding Biotechnology Co., Ltd., and the trial is expected to be available by the end of the year.
Military Medical Research Institute and Consino Bio: Adenovirus Vector Vaccine The Ad5-nCoV candidate vaccine, developed jointly by the Chinese Academy of Military Medicine and Consino Corporation, is a genetically engineered vaccine candidate that expresses the S-spike protein of the new coronavirus with type 5 adenovirus as a "vector".
the vaccine is based on Consino Bio's adenovirus-based viral vector vaccine technology platform.
March 16, Chen Wei's team launched the first phase of clinical trials in Wuhan, the world's first new crown vaccine to enter the clinical research phase.
12, the second phase of clinical trials of the vaccine was launched.
August 11, the vaccine was granted a national patent, becoming the first new crown vaccine to enter the clinical patent.
, the new crown vaccine developed by Chen Wei's team has entered the phase III international clinical trial stage.
, the United States, Europe and other countries of the new crown candidate vaccine Pfizer (USA) / BioNTech (Germany) Pfizer and BioNTech have jointly developed four candidate vaccines, of which BNT162b1 and BNT162b2 have been granted fast-track status by the FDA.
July 27, BNT162b2 officially launched phase IIb/III clinical trials for up to 30,000 volunteers.
September 7, BioNTech and Pfizer received approval from the PAUL EHRLICH Institute to conduct a phase 2/3 vaccine study of the new crown candidate vaccine BNT162b in Germany.
if the results are good, they will submit a listing application as early as October this year.
is expected to produce 100 million doses of vaccine by the end of 2020 and more than 1.3 billion doses by the end of 2021.
The Japanese government has agreed to buy 120 million doses of vaccine to cover about half of the country's population; the U.S. government will pay $1.95 billion for 100 million doses of the vaccine, and will continue to buy 500 million doses to provide free vaccines to the American public.
August 27, Fosun Pharma and BioNTech entered into a supply cooperation agreement to supply 10 million doses of BNT162 vaccine candidates to the Hong Kong Special Administrative Region of China and the Macao Special Administrative Region of China after clinical trials confirmed the safety and effectiveness of the BNT162 candidate vaccine and obtained regulatory approval.
, Fosun Pharma and China Pharmaceutical Holdings signed a strategic logistics cooperation agreement on bioNTech's development of mRNA vaccines, which will jointly promote the commercialization of vaccines and supply chain services.
Moderna/National Institutes of Health (U.S.) The National Institutes of Health and Moderna developed the mRNA vaccine, which relies on injecting mRNA, a component of the virus's genetic material, into human cells.
other vaccines, it does not use real viruses, but creates proteins that mimic the new coronavirus.
success, mRNA-1273 would be the first RNA vaccine to be approved for use in humans.
I/II clinical trials have been shown to be safe and immunogenic, but more than half of the participants had side effects, including fatigue, chills, headaches, muscle pain and injection site pain, and the higher the dose, the more serious the side effects.
Phase 3 clinical trial began on July 27 and recruited 30,000 volunteers from 89 clinical research centers in the United States.
May 2, Moderna and Lonza announced a 10-year strategic cooperation agreement to increase the production capacity of mRNA-1273.
, with Lonza's help, Moderna is expected to deliver 500 million to 1 billion doses of vaccine to society each year from 2021.
said volunteer recruitment is expected to be completed in September and Phase III clinical trial data will be released by the end of the year.
night of August 11, Moderna announced that it had reached an agreement with the U.S. government to purchase 100 million doses of the vaccine, worth up to $1.525 billion, and that the government had the option to purchase an additional 400 million doses.
AZD1222, a candidate for the Jenner Institute at AstraZeneta/Oxford University (UK), is a genetically engineered product based on chimpanzee adenovirus vectors.
in early trials, the vaccine triggered antibody and T-cell reactions.
Phase 3 clinical trial already has 4,000 volunteers in the UK and is expected to recruit an further 10,000.
5,000 volunteers for a clinical trial in Brazil.
if the trial is successful, it could be available to the first users in September.
So far, AstraZenecom has reached landmark agreements with the European Alliance for Inclusive Vaccines (IVA), led by Germany, France, Italy and the Netherlands, the Alliance for Innovation in Epidemiology (CEPI), the Alliance for Vaccines (Gavi) and the Serum Institute of India (SII), pledging to supply more than 2 billion doses of vaccines this year, with most orders expected to be delivered this year.
-V vaccine is the world's first approved vaccine.
Satellite-V was developed by the Moscow-Gamaria National Research Centre for Epidemiology and Microbiology in cooperation with the Russian Direct Investment Fund.
, Russian President Vladimir Putin revealed in a video conference that the vaccine, known as Sputnik-V, had been approved by the Russian Ministry of Health after nearly two months of human trials.
Dmitriev, president of the Russian Direct Investment Fund, said more than 20 countries have applied to buy vaccines.
also noted that Russia has agreed to produce vaccines in five countries, with an existing capacity of 500 million doses a year.
Recently, Russian researchers reported the results of phase I/II clinical trials of the vaccine in The Lancet, in which 76 participants between the ages of 18 and 60 were observed for 42 days after being vaccinated, all of whom produced antibodies to the new coronavirus within three weeks, with levels of antibody response similar to those of naturally ill people.
also looked at T-cell reactions associated with the immune system, and the results showed that the vaccine produced t-cell reactions within 28 days.
According to Russian reports, on September 7, local time, Russia's first new coronavirus vaccine "satellite-V" after passing the necessary quality tests have been approved for civilian flow, is expected to be delivered to the regions in the near future.
More than 1.8 million Russians have been vaccinated against the flu, according to a news release on the website of Russia's Consumer Protection and Public Interest Supervision Agency, according to the Russian satellite news agency on September 8.
3. In addition to the above-mentioned vaccines that have entered Phase III clinical trials, more than 160 candidate vaccines are in different stages of testing, and several vaccines are about to start Phase III clinical trials: Novavax (USA) NVX-CoV2373 is expected to start Phase III in September Clinical trials, with Johnson and Johnson (U.S.) Ad26.COV2.S planning to begin phase III trials on 60,000 volunteers in late September, and phase 3 clinical trials of new crown vaccines from Mediago, Inovio Pharmaceuticals, CureVac and others are expected to start this year.
will continue to intensify as Russia's new coronavirus vaccine, Satellite-V, is officially put into circulation and mass inoculated.
while at least one of the first experimental vaccines to enter Phase 3 is likely to be approved for COVID-19 prevention, there is no guarantee that any of these candidate vaccines will actually work.
, however, other candidate vaccines will soon enter the advanced stages of clinical trials, and mass vaccination of COVID-19 vaccines is still expected.
reference source 1. Endpoints News ranks all 28 players in the Covid-19 vaccine race. Here's how it stacks up today2. The first domestic new crown vaccine debuted, the box information volume is very large 3. Russia's first batch of new crown vaccine has been put into civilian circulation in the near future will be delivered to all regions.